Instil Bio Inc TIL

Healthcare Biotechnology

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.

NDAQ:TIL - Post by User

Instil Bio Inc

Bullboard Posts

Comment by Giverbulletson Jan 24, 2012 12:17pm

520 Views

Post# 19442057

RE: Bill's New Presentation

Well, I'll take production over resouces right now. Let's hope they stick to that plan and start making some money this year!!! Maybe they can add to the pad and work up to 50k oz for next year and pay for pad B.

Is there a new vid of this somewhere?

Giver.

Bullboard Posts

Visionstate set to leverage success in the U.S. market